Immunocore (ADR) (IMCR)
Develops ImmTAX-based immunotherapies and sells KIMMTRAK for eligible uveal melanoma patients.
$31.50
vs last close−0.92 (−2.83%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 101.18% | 52.11M ADS | |
|---|---|---|---|
| 145 holders · as of Jun 30, 2026 | |||
| Insiders | 17.94% | 9.24M ADS | |
| 6 holders · as of Feb 19, 2026 | |||
| Strategic holders | 8.61% | 4.43M ADS | |
| 2 holders · as of Mar 19, 2025 | |||
| Adds to | 127.73% | ||
51.50M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 127.73%; nothing is left for Other.
13F, as of Jun 30, 2026
145 holders · 52.11M shares · 26 new positions · 78 increased · 40 reduced · 34 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Wellington Management Group LLP | 5.72M | 11.11% | +1.02M | Aug 14, 2026 |
| RTW Investments, LP | 4.87M | 9.46% | 0 | Aug 14, 2026 |
| FMR LLC | 4.31M | 8.36% | −521.9K | Aug 13, 2026 |
| Primecap Management Co/CA/ | 3.64M | 7.06% | −55.0K | Aug 14, 2026 |
| Bellevue Group AG | 2.79M | 5.41% | −8.6K | Aug 14, 2026 |
| Tang Capital Management LLC | 2.65M | 5.14% | 0 | Aug 14, 2026 |
| Vestal Point Capital, LP | 1.80M | 3.50% | −966.9K | Aug 14, 2026 |
| Two Sigma Investments, LP | 1.65M | 3.20% | +627.7K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Wellington Management Group LLP | 10.20% | 5.13M | 13G | Aug 5, 2025 |
| Jallal Bahija | 8.20% | 4.49M | 13G | Feb 14, 2025 |
| Primecap Management Co/CA/ | 7.51% | 3.77M | 13G | Aug 14, 2025 |
| Bellevue Group AG | 5.60% | 2.80M | 13G | Nov 14, 2025 |
| Vestal Point Capital, LP | 5.50% | 2.77M | 13G | May 15, 2026 |
| Tang Capital Management, LLC | 5.20% | 2.61M | 13G | Oct 24, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Feb 18, 2026 | David M. Bermanofficer: HEAD OF R&D | Sale | 5,965 | $32.35 | 5,859 |
| Feb 18, 2026 | Tina Amber st Legerofficer: CHIEF HR OFFICER | Sale | 1,000 | $32.35 | 1,119 |
| Feb 18, 2026 | John Gollofficer: SVP, FINANCE & CAO | Sale | 698 | $32.35 | 653 |
| Feb 18, 2026 | Bahija Jallaldirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 11,474 | $32.35 | 12,343 |
| Dec 4, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 31,341 | $40.26 | 0 |
| Dec 5, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 572 | $40.14 | 0 |
| Nov 26, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 69,404 | $40.12 | 0 |
| Nov 28, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 5,521 | $40.09 | 0 |
| Nov 25, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 18,020 | $40.03 | 0 |
| Nov 24, 2025 | David M. Bermanofficer: HEAD OF R&D | Sale | 100 | $40.00 | 0 |
House and Senate disclosures
Not reported.